<ul>
	<li><strong>Serious infections</strong>: Adalimumab should not be started during an active infection. If an infection develops, should be carefully monitored and if infection becomes serious Adalimumab should be stopped.</li>
	<li><strong>Invasive fungal infections</strong>: For patients who develop a systemic illness on Adalimumab, empiric antifungal therapy should be considered for those who reside or travel to regions where mycoses are endemic</li>
	<li><strong>Malignancies</strong>: Incidence of malignancies was greater in Adalimumab-treated patients than in controls</li>
	<li><strong>Anaphylaxis or serious allergic reactions</strong>&nbsp;may occur Hepatitis B virus reactivation: HBV carriers should be monitored during and several months after therapy. If reactivation occurs, Adalimumab should be stopped and antiviral therapy should be started</li>
	<li><strong>Demyelinating disease</strong>: Exacerbation or new onset, may occur Cytopenias, pancytopenia: Patients should be advised to seek immediate medical attention if symptoms develop, and should be considered stopping Adalimumab</li>
	<li><strong>Heart failure</strong>: Worsening or new onset, may occur</li>
	<li><strong>Lupus-like syndrome</strong>: Adalimumab should be stopped if syndrome develops</li>
</ul>